Autolus Therapeutics vs Mesoblast
Mesoblast is the larger business, with $120m of revenue in fiscal 2026 against $75.4m for Autolus Therapeutics (1.6 times as much). Autolus Therapeutics grew faster (644.9% against 599.2%). Mesoblast kept more of each dollar of sales as profit: a net margin of -47.8% against -381.4%. Autolus Therapeutics carries less debt relative to equity (0.0% against 22.8%).
| Latest fiscal year | Autolus TherapeuticsAUTL, 2025 | MesoblastMESO, 2026 |
|---|---|---|
| Revenue | $75.4m | $120m |
| Revenue growth | 644.9% | 599.2% |
| Net income | −$288m | −$57.5m |
| Operating margin | -358.9% | — |
| Net margin | -381.4% | -47.8% |
| Return on equity | -95.0% | -9.9% |
| Free cash flow | −$303m | −$44.7m |
| Cash | $104m | $103m |
| Total debt | $0 | $130m |
| Debt to equity | 0.0% | 22.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 754 | — |
| Market value | $371m | $1.91bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 1 sales | 24 buys, 0 sales |